RT Journal Article
SR Electronic
T1 Revisiting the effects of MDR1 Variants using computational approaches
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.09.02.23294978
DO 10.1101/2023.09.02.23294978
A1 Gutman, Tal
A1 Tuller, Tamir
YR 2023
UL http://medrxiv.org/content/early/2023/09/03/2023.09.02.23294978.abstract
AB P-glycoprotein, encoded by the MDR1 gene, is an ATP-dependent pump that exports various substances out of cells. Its overexpression is related to multi drug resistance in many cancers. Numerous studies explored the effects of MDR1 variants on p-glycoprotein expression and function, and on patient survivability. T1236C, T2677C and T3435C are prevalent MDR1 variants that are the most widely studied, typically in-vitro and in-vivo, with remarkably inconsistent results. In this paper we perform computational, data-driven analyses to assess the effects of these variants using a different approach. We use knowledge of gene expression regulation to elucidate the variants’ mechanism of action. Results indicate that T1236C increases MDR1 levels by 2-fold and is correlated with worse patient prognosis. Additionally, examination of MDR1 folding strength suggests that T3435C potentially modifies co-translational folding. Furthermore, all three variants reside in potential translation bottlenecks and likely cause increased translation rates. These results support several hypotheses suggested by previous studies. To the best of our knowledge, this study is the first to apply a computational approach to examine the effects of MDR1 variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported in part by a fellowship from the Edmond J. Safra Center for Bioinformatics at Tel-Aviv University and by the Koret-UC Berkeley-Tel Aviv University initiative in Computational Biology and Bioinformatics.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes